Pharmacodynamics of mutant-IDH1 inhibitors in glioma patients probed by in vivo 3D MRS imaging of 2-hydroxyglutarate

Inhibitors of the mutant isocitrate dehydrogenase 1 (IDH1) entered recently in clinical trials for glioma treatment. Mutant IDH1 produces high levels of 2-hydroxyglurate (2HG), thought to initiate oncogenesis through epigenetic modifications of gene expression. In this study, we show the initial evi...

Descripción completa

Detalles Bibliográficos
Autores principales: Andronesi, Ovidiu C., Arrillaga-Romany, Isabel C., Ly, K. Ina, Bogner, Wolfgang, Ratai, Eva M., Reitz, Kara, Iafrate, A. John, Dietrich, Jorg, Gerstner, Elizabeth R., Chi, Andrew S., Rosen, Bruce R., Wen, Patrick Y., Cahill, Daniel P., Batchelor, Tracy T.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2018
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5902553/
https://www.ncbi.nlm.nih.gov/pubmed/29662077
http://dx.doi.org/10.1038/s41467-018-03905-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5902553/
https://www.ncbi.nlm.nih.gov/pubmed/29662077
http://dx.doi.org/10.1038/s41467-018-03905-6

Ejemplares similares